MVMaarten A. Vink

Maarten A. Vink

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maarten A. Vink has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction

    by Nicola S. Vos, Nick D. Fagel, Giovanni Amoroso, Jean-Paul R. Herrman, Mark S. Patterson, Lieuwe H. Piers, René J. van der Schaaf, Ton Slagboom, Maarten A. Vink


  • Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention in Multivessel Coronary Disease Is Primarily Related to Stent Failure

    by Maarten A. Vink, Nicola S. Vos, Maurits T. Dirksen, Maarten J. Suttorp, Ton Slagboom, Mark S. Patterson, Ferdinand Kiemeneij, GertJan Laarman

    Objectives: Our aim was to investigate the risk of events related to non‐culprit lesions after primary percutaneous coronary intervention (PCI) in patients with multivessel coronary disease (MVD).Background: In patients undergoing primary PCI for ST‐elevation myocardial infarction (STEMI) who are diagnosed with MVD, the optimal treatment strategy is currently under debate. Although observational data exposed an increased risk of multivessel PCI in the acute phase of STEMI, 2 recently published randomized controlled trials showed a reduction of death or recurrent myocardial infarction (MI) after preventive PCI of non‐culprit lesions when compared with culprit‐lesion PCI only.Methods: We performed a post‐hoc analysis of 279 patients with MVD included in the Paclitaxel‐Eluting Stent versus Conventional Stent in Myocardial Infarction with ST‐Segment Elevation (PASSION) trial. We analyzed the incidence and cause of recurrent MI. Recurrent MI due to stent failure was assumed in the event of definite or probable stent thrombosis.Results: After 5 years, 14 patients (5.7%) with MVD had a recurrent MI versus 17 (5.4%) patients with 1‐vessel disease (HR 1.06, 95%CI 0.52–2.15, P = 0.87). The majority of events was attributable to stent failure, while of the remaining 6 events, only 1 was proven to originate from a lesion that was judged significant at enrolment.Conclusions: In this post‐hoc analysis of the PASSION trial, recurrent MI in patients with MVD was mainly related to stent failure rather than a new event originating from a significant stenosis in a non‐culprit coronary artery. (J Interven Cardiol 2015;28:523–530)


  • REVascularization with paclitaxEL‐coated balloon angioplasty versus drug‐eluting stenting in acute myocardial infarcTION—A randomized controlled trial: Rationale and design of the REVELATION trial

    by Nicola S. Vos, Rene J. van der Schaaf, Giovanni Amoroso, Jean‐Paul R. Herrman, Mark S. Patterson, Ton Slagboom, Maarten A. Vink

    Aim: In primary percutaneous coronary intervention (PPCI) for ST‐elevation myocardial infarction (STEMI), stenting has proved to reduce the need for repeat revascularization compared with balloon angioplasty alone. The incidence of cardiac death or recurrent myocardial infarction, though, is not reduced by stenting. This is in part attributable to stent‐related complications like stent thrombosis which may occur even years after implantation. A strategy of drug coated balloon (DCB) angioplasty without stenting would abolish the potential disadvantages of stent implantation while reducing the probability of restenosis observed in plain old balloon angioplasty. Our aim is to evaluate the efficacy and safety of a DCB only strategy versus drug‐eluting stents (DES) in PPCI for STEMI.Study design: The REVELATION trial is a prospective, single center, randomized study, in which 120 patients presenting with STEMI will be allocated to treatment with a DCB versus DES. Appertaining to the established prognostic value of fractional flow reserve (FFR) rather than angiographic lesion severity, the functional assessment of the infarct‐related lesion by FFR at 9 months after initial treatment is the primary end point. Assuming an FFR value of 0.90 after stenting and an increased risk of adverse events if post‐PCI FFR <0.85, we decided to accept an FFR value of ≥0.85 after DCB only at follow‐up as noninferiority margin. Secondary end points include major adverse cardiac events up to 5‐year follow‐up.Conclusion: Our trial will address the efficacy and safety of DCB angioplasty versus DES in the setting of PPCI for STEMI. The REVELATION trial will introduce the recognized prognostic significance of physiologic assessment of the infarct‐related lesion by FFR at 9 months follow‐up as primary end point.


  • Lack of long‐term clinical benefit of thrombus aspiration during primary percutaneous coronary intervention with paclitaxel‐eluting stents or bare‐metal stents: Post‐hoc analysis of the PASSION‐trial

    by Maarten A. Vink, Maurits T. Dirksen, Jan G.P. Tijssen, Maarten J. Suttorp, Mark S. Patterson, Nan van Geloven, Alexander J. Ijsselmuiden, Ton Slagboom, Ferdinand Kiemeneij, Gerrit J. Laarman

    Background: Although current clinical guidelines recommend the use of thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI), previous studies evaluating TA demonstrated contradictory results. The aim of this study was to evaluate long‐term clinical outcome after TA in adjunct to PPCI for acute ST‐segment myocardial infarction (STEMI), as compared with conventional treatment, with the use of paclitaxel‐eluting stents or bare‐metal stents. Methods: We analyzed data of the PASSION trial, in which 619 patients with STEMI were randomly assigned to a paclitaxel‐eluting stent or a bare‐metal stent. TA was performed in 311 patients (50.2%). Clinical endpoints at 2 years were compared between patients who received TA during PPCI with patients who underwent conventional PPCI. The primary outcome of interest was a composite of cardiac death, recurrent myocardial infarction (MI), or target‐lesion revascularization (TLR). A propensity score model was made to account for baseline differences that could have affected the probability of performing TA. Results: Complete follow‐up was available for 598 patients (96.6%). The cumulative incidence of the combined outcome measure of cardiac death, recurrent MI, or TLR was 40 (13.0%) in the TA group and 41 (13.5%) in the conventional PPCI group (HR 0.96; 95% CI 0.62–1.47; P = 0.84). Also after adjusting for propensity score, no significant difference in event rate was observed between both treatment groups. Conclusions: In this post‐hoc analysis of the PASSION trial, TA in adjunct to PPCI did not affect rates of major adverse cardiac events at 2 years follow‐up, as compared with conventional PPCI.


  • Patency of Paclitaxel-Eluting Versus Bare Metal Stents Long Term After Implantation in Acute ST-Segment Elevation Myocardial Infarction

    by Maarten A. Vink, Ferdinand C. Van Nooijen, Gerrit J. Laarman, Maarten J. Suttorp, Jan G. Tijssen, Ton Slagboom, Mark S. Patterson, Rene J. Van Der Schaaf, Ferdinand Kiemeneij, Giovanni Amoroso, et al.


  • Routine use of the transradial approach in primary percutaneous coronary intervention: procedural aspects and outcomes in 2209 patients treated in a single high-volume centre

    by M. A. Vink, Giovanni Amoroso, Maurits T Dirksen, Rene J van der Schaaf, Mark S Patterson, J. G. P. Tijssen, Ferdinand Kiemeneij, Ton Slagboom

    Objective To examine the feasibility of a routine transradial approach (TRA) in primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI). Design A single-centre observational study with prospective data collection. Setting A high-volume interventional centre in Amsterdam, The Netherlands. Patients Procedural data were analysed for 2209 consecutive patients presenting with STEMI without cardiogenic shock, between January 2001 and December 2008. Interventions PPCI routinely performed by the TRA. Main Outcome Measures The primary outcomes of interest were the need for crossover to another vascular access site, the achievement of procedural success and their trends over time. Secondary outcome measures were trends in total procedural duration, fluoroscopy times and use of equipment. Results In a total of 2209 procedures the radial artery was the primary access site, comprising 96.1% of all procedures performed during the study period. In 84 cases (3.8%) access site crossover was needed. Crossover rates decreased from 5.9% in 2001–2 to 1.5% in 2007–8 (p=0.001). The procedural success rate was 94.1%, which remained stable over the years. Despite an increased complexity of PPCI (more non-left anterior descending infarct-related arteries, thrombus aspiration and multivessel PPCI), total procedural duration decreased from 38 min (IQR 28–50) in 2001–2 to 24 min (18–33) in 2007–8, pConclusions Systematic use of the TRA in PPCI yields low access site crossover, high procedural success rates and excellent procedural performances. It can therefore represent the primary access site in the vast majority of STEMI patients.


  • A randomized comparison of manual versus mechanical thrombus removal in primary percutaneous coronary intervention in the treatment of ST‐segment elevation myocardial infarction (TREAT‐MI)

    by Maarten A. Vink, Mark S. Patterson, Jeroen van Etten, Alexander J.J. Ijsselmuiden, Maurits T. Dirksen, Giovanni Amoroso, Ton Slagboom, GertJan Laarman, Ferdinand Kiemeneij

    Objectives: The objective of this study was to compare the efficacy and long‐term clinical outcome of manual thrombus aspiration with the Export catheter (Medtronic, Minneapolis, MN) versus mechanical thrombus cutting/aspiration with the X‐sizer system (eV3, White Bear Lake, MN) in primary percutaneous coronary intervention (PPCI). Background: In PPCI for acute ST‐segment elevation myocardial infarction (STEMI), markers of myocardial reperfusion are improved with adjunctive thrombectomy. Previous studies of different devices showed a variability in performance, suitability, and short‐term clinical outcome. In current literature, no direct comparison is available. Methods: We prospectively randomized 201 patients admitted for PPCI for STEMI to either the Export catheter or the X‐sizer prior to stent deployment. Technical success in advancing to and across the lesion, improvement of flow, reduction of thrombus, and the effect on ST‐segment resolution were examined. The primary endpoint of the follow‐up study was the combined endpoint of cardiac death, recurrent myocardial infarction (MI), or target‐vessel revascularization (TVR) at 3 years. Results: Although the Export catheter was more successfully deployed, other procedural parameters were similar with a trend toward better ST‐segment resolution (56.6% vs. 44%; P = 0.06) as compared to the X‐sizer system. The occurrence of the primary clinical endpoint at 3 years was 22.2% and 18.6%, respectively (HR 1.20; 95% CI 0.65–2.22; P = 0.35). Conclusion: Despite shorter procedural times, better lesion crossing, and fewer complications, both surrogate endpoints as well as 3‐year clinical follow‐up were similar with the use of the Export catheter as compared to the X‐sizer system.


  • 5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction

    by Maarten A. Vink, Maurits T. Dirksen, Maarten J. Suttorp, Jan G.P. Tijssen, Jeroen van Etten, Mark S. Patterson, Ton Slagboom, Ferdinand Kiemeneij, Gerrit J. Laarman